Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Burkitt Lymphoma 25Prostatic Neoplasms 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Large B-Cell, Diffuse 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia, Biphenotypic, Acute 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell 4Plasmablastic Lymphoma 3Lymphoma, T-Cell 3Lymphoma, Follicular 3Lymphoma 3Hodgkin Disease 3Multiple Myeloma 2Melanoma 2Lymphoma, Large-Cell, Anaplastic 2Immunoblastic Lymphadenopathy 2Enteropathy-Associated T-Cell Lymphoma 2Carcinoma, Merkel Cell 2Carcinoma, Basal Cell 2Blast Crisis 2Vasculitis, Central Nervous System 1Urogenital Neoplasms 1Stiff-Person Syndrome 1Stage II Prostate Adenocarcinoma 1Rasmussen subacute encephalitis 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1Oropharyngeal Neoplasms 1Opsoclonus-Myoclonus Syndrome 1Neuromyelitis Optica 1

Interventions

prednylidene 1deltacortene 1cabazitaxel 1XRP6258 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone-Resistant Prostate Cancer × deltacortene × Clear all
NCT02844582 2021-01-25

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of California, Davis

Phase 2 Terminated
2 enrolled 5 charts
Genitourinary

Hormone-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡